Icrucumab,Abbexa,abx831212
Icrucumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting FLT1/VEGFR-1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Host
Human
Reactivity
Human
Application
ELISA, WB
Conjugate
Unconjugated
Platform ID
BAB112039743
Abbexa
Contact
Tel: +44 (0) 1223 755950
Fax: +44 (0) 1223 755951
Email:
Product Specifications
Specifications
NameIcrucumab
Cat. No.abx831212
HostHuman
IsotypeIgG1 Kappa
ReactivityHuman
ConjugationUnconjugated
ApplicationELISA, WB
Working DilutionsOptimal dilutions/concentrations should be determined by the end user.
ClonalityMonoclonal
ConcentrationBatch-dependent, typically between 0.5-2.0 mg/ml.
TargetFLT1/VEGFR-1
PurityPurified from cell culture supernatants by Protein A/G chromatography.
Appearance/FormLiquid
Formulation0.01 M PBS. pH 7.4.
StorageAliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Regulatory StatusResearch Use Only
Category Paths
- Products>Primary Antibodies>Biosimilar Antibodies
Request a product
Please provide the required information below so that we can quickly source your products.